Engflag

Cardiocare

Quick links to important sections

Cardiocare

Cardiocare_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cardiocare

What is Cardiocare? Definition and Pharmaceutical Class

Property Description
Active Ingredients Docosahexaenoic Acid (DHA), Eicosapentaenoic Acid (EPA)
Form Oral capsule (Softgel)
Pharmacological Class Essential fatty acid supplement, Lipid-regulating agent
General Purpose Nutritional support for cardiovascular health
Origin Natural, Marine-derived (Fish Oil/Salmon Fish Oil)

Cardiocare is a composite essential fatty acid supplement and lipid-regulating agent that delivers concentrated marine-derived polyunsaturated fats. It is supplied as an oral capsule or softgel, a form designed for convenient oral ingestion and subsequent absorption in the digestive system. This preparation is classified within the pharmacological group of nutritional agents because its primary role is the provision of vital dietary components rather than acting as a synthetic drug.

Composition and Natural, Marine-Derived Origin

Cardiocare is a combination product containing the two primary active ingredients: Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA). These fatty acids are sourced from a lipid matrix of Fish Oil and Salmon Fish Oil, confirming the preparation's natural origin. The formulation specifically concentrates DHA and EPA, which are recognized as essential nutrients; the body has a limited capacity to synthesize them from other dietary fats, making direct supplementation crucial. Consumption of these fatty acids is fundamental to maintaining normal cellular functions, particularly within the nervous and cardiovascular systems.

General Purpose as a Nutritional Support Agent

The general purpose of Cardiocare is to act as a nutritional support agent focused on maintaining cardiovascular health and systemic metabolic balance. It achieves this by supplying the building blocks needed to support cell function and healthy metabolic balance. The underlying principle is that by providing these essential fatty acids, Cardiocare helps the body modulate its own systems, particularly by integrating into cell membranes to maintain proper structure and flexibility. Supplementation with Omega-3s is a recognized strategy, noted for its role in supporting healthy lipid levels. Thus, the preparation supports the optimization of the body's native lipid processes, often utilized in the context of maintaining a healthy diet.

Regulatory References

  1. NIH - Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)
  2. NIH Office of Dietary Supplements - Omega-3 Fatty Acids Fact Sheet

What side effects are possible with Cardiocare?

Possible side effects and safety information for Cardiocare

The safety profile of Cardiocare (DHA/EPA) is based on the classification of adverse reactions documented in official government regulatory labels. These effects are grouped by frequency and the physiological system affected.

Most documented adverse events are Common (affecting 1 to 10 users in 100) and involve the Gastrointestinal system. Examples include dyspepsia (indigestion), flatulence, and nausea. These effects are often noted as being more common during the initial phase of treatment.

Frequency Classification Associated Organ System (SOC) Key Adverse Reactions (Regulatory Terminology)
Common Gastrointestinal disorders Dyspepsia, Flatulence, Nausea
Common Hepatobiliary disorders Elevated liver enzymes (ALT, AST)
Uncommon Nervous system disorders Dysgeusia (taste disturbance), Dizziness

Documented Safety Considerations

The official label documents certain clinically significant safety considerations. The preparation is associated with an increased bleeding risk, a key concern when used concurrently with other medications that affect blood clotting, requiring the monitoring of coagulation parameters. The safety profile also includes the documented possibility of elevated liver enzymes, necessitating periodic monitoring in patients, especially those with pre-existing hepatic impairment. Furthermore, an increased risk of new-onset Atrial Fibrillation has been observed, particularly with higher doses. Due to its marine-derived origin, use is contraindicated in individuals with known fish or shellfish allergies.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define an overdose of Cardiocare (DHA/EPA) as potentially leading to an increase in the severity of documented adverse effects, necessitating immediate actions and supportive care.

Documented Overdose Manifestations

Overdose may present with exaggerated gastrointestinal and cutaneous disorders. Documented symptoms include vomiting, constipation, and skin reactions. Regulatory labeling also notes the potential for metabolic abnormalities, such as an increase in LDL cholesterol and elevation of liver enzymes (ALT and AST).

Severe Outcomes and Emergency Action

High exposure can lead to severe systemic and coagulation risks. These include an increased risk of bleeding due to prolonged bleeding time, and the potential for serious cardiac complications such as recurrent Atrial Fibrillation (AF) or Flutter.

Urgent medical attention must be sought if symptoms are severe or if they do not resolve after the product is discontinued. The presence of serious outcomes, particularly suspected Atrial Fibrillation, requires immediate medical evaluation.

Management and Monitoring

No specific antidote is known for overdose with omega-3-acid ethyl esters. Management listed in regulatory documents is limited to symptomatic and supportive treatment. Monitoring requirements include the periodic observation of coagulation parameters and liver enzymes (ALT/AST) to manage documented risks.

Therapeutic Uses of Cardiocare

Main Uses and Benefits of Cardiocare

Cardiocare is a pharmaceutical intervention primarily utilized in the management of chronic cardiovascular conditions. It is designed to support heart function and maintain vascular stability in patients diagnosed with specific circulatory disorders.

Primary Indications

The medication is most frequently prescribed for the following conditions:

  • Chronic Heart Failure: Cardiocare is used to improve the heart's ability to pump blood effectively throughout the body, particularly in cases where the heart muscle has weakened over time.
  • Hypertension (High Blood Pressure): It assists in the long-term management of elevated blood pressure, helping to reduce the workload on the heart and the pressure exerted on arterial walls.
  • Stable Angina Pectoris: The treatment is used to manage symptoms of chest pain associated with reduced blood flow to the heart muscle during physical exertion or stress.

Therapeutic Benefits

The clinical objective of Cardiocare is to stabilize cardiovascular health and prevent the progression of underlying heart disease. The primary benefits observed during treatment include:

  • Improved Cardiac Efficiency: By optimizing the force and rhythm of heart contractions, the medication helps ensure that vital organs receive an adequate supply of oxygenated blood.
  • Vascular Relaxation: Cardiocare promotes the dilation of blood vessels, which facilitates smoother blood flow and decreases peripheral resistance.
  • Symptom Management: Regular use can lead to a reduction in common symptoms associated with heart strain, such as shortness of breath, persistent fatigue, and swelling in the lower extremities (edema).
  • Long-term Cardiovascular Protection: Consistent management of blood pressure and heart strain contributes to a lower risk of acute cardiovascular events and secondary complications related to chronic heart disease.

Regulatory References

  1. NIH MedlinePlus overview of Omega-3 Fatty Acids

Eligibility and Restrictions for Use

Cardiocare (low-dose acetylsalicylic acid) is primarily indicated to reduce the risk of cardiovascular events, such as myocardial infarction (heart attack) and stroke, in patients who have already experienced such events or who are considered high-risk by a healthcare provider.

Contraindications

Cardiocare is not appropriate for all patients. Do not use this medication if you have:

  • A known hypersensitivity or allergy to aspirin or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).
  • An active or recurrent history of peptic ulcers or gastrointestinal bleeding.
  • A predisposition to bleeding, such as a severe blood or clotting disorder (e.g., hemophilia).
  • Severe liver or kidney impairment.
  • Severe heart failure (NYHA Grade III or IV).
  • Are in the first or third trimester of pregnancy.
  • Are under 16 years of age, due to the risk of Reye's syndrome following a viral infection.

Precautions and Special Considerations

Caution is advised in elderly patients, those with a history of asthma or nasal polyps, mild-to-moderate heart failure, controlled hypertension, or chronic gastrointestinal disease (like Crohn's disease or ulcerative colitis). Always consult a healthcare professional before starting Cardiocare, especially if taking other medications that increase bleeding risk, such as anticoagulants or other antiplatelet agents.

What should I know about interactions with other medicines?

Cardiocare (commonly a low-dose aspirin formulation) may interact with a wide range of other medications, supplements, and substances. Always inform your healthcare provider and pharmacist about all products you use to prevent potentially serious interactions.

Medications with Increased Bleeding Risk

Concomitant use with other agents that affect blood clotting can increase the risk of bleeding, including gastrointestinal hemorrhage. Avoid or use with extreme caution:

Interacting Agents Potential Effect
Anticoagulants (e.g., Warfarin, Heparin) Enhanced anti-clotting effect, significantly higher bleeding risk
Other Antiplatelet agents (e.g., Clopidogrel) Additive antiplatelet effects, increased bleeding risk
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (e.g., Ibuprofen, Naproxen) Increased risk of gastrointestinal side effects, including ulcers and bleeding
Selective Serotonin Reuptake Inhibitors (SSRIs) Increased risk of bleeding
Corticosteroids (oral) Increased risk of gastrointestinal ulceration and bleeding

Other Significant Drug Interactions

Cardiocare can also affect the efficacy and safety of other drug classes:

  • Antihypertensives (e.g., ACE Inhibitors, Diuretics): NSAIDs, including aspirin, may reduce the blood pressure-lowering effect of some antihypertensive medications and may increase the risk of kidney impairment.
  • Methotrexate: Cardiocare can decrease the elimination of methotrexate, leading to potentially toxic levels in the body.
  • Medicines for Gout (e.g., Probenecid, Sulfinpyrazone): Cardiocare can diminish the effect of these uricosuric agents.
  • Valproate: Cardiocare may increase the concentration of Valproate, raising the risk of toxicity.

Interactions with Food and Herbal Products

  • Alcohol: Consuming alcohol while taking Cardiocare may increase the risk of gastrointestinal bleeding.
  • Herbal Supplements: Certain supplements, such as Ginkgo Biloba or Garlic, may possess antiplatelet properties and could increase the risk of bleeding when combined with Cardiocare.

Mechanism of Action

How Cardiocare Works

Cardiocare, containing Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA), operates through a multi-modal mechanism that modifies genetic signaling and alters cellular membrane structure to influence lipid and inflammatory homeostasis.

Genetic Control of Lipid Synthesis

The active ingredients function as ligands to activate the nuclear receptor PPARα and suppress the transcription factor SREBP-1c in the liver. This action modulates the genetic machinery responsible for fat metabolism, reducing the liver's synthesis and secretion of Triglycerides via VLDL, which modifies circulating lipid concentrations.

Remodeling of the Eicosanoid Pathway

EPA and DHA integrate into cell membranes, competitively displacing Arachidonic Acid (AA). The resulting shift in the eicosanoid cascade produces less pro-inflammatory mediators and facilitates the creation of specialized Resolvins and Protectins. This action modulates vascular signaling and facilitates the active resolution of systemic inflammation.

Structural Modulation of Cardiac Function

DHA incorporates into the phospholipids of myocardial cell membranes. This structural remodeling alters the biophysical properties of the membrane, consequently modulating the function of embedded proteins like certain cardiac ion channels. This mechanism contributes to the modulation of electrical excitability and refractoriness in the heart muscle cells.

Dosage and Administration Information

Cardiocare, a prescription-grade omega-3-acid ethyl ester preparation, is exclusively administered via the oral route as a 1-gram soft gelatin capsule. The general principle of its use is as an adjunct to diet for the management of elevated blood triglyceride levels in adults, in accordance with established dosage and administration protocols.

Standard Dosage and Frequency

The standard maximum recommended daily dose for adults is 4 grams. This total daily dose may be administered in one of two ways: either as a single 4-gram dose once daily (four capsules) or as two 2-gram doses (two capsules) taken twice daily.

Administration Requirements and Duration

For proper use, Cardiocare capsules must be administered with meals. The integrity of the dosage form is critical; therefore, the capsules must be swallowed whole and should not be crushed, dissolved, or chewed.

The duration of use is defined by ongoing patient assessment. Continued administration requires periodic laboratory monitoring of triglyceride levels. Therapy is generally discontinued if an adequate reduction in triglyceride levels is not observed after 2 months of treatment. For specific populations, the safety and effectiveness of this formulation have not been established in pediatric patients.

Recent Clinical Evidence

Research evidence / Overview of studies

Evidence for Osteoarthritis

Studies evaluated whether the drug was associated with changes in the symptoms of osteoarthritis (OA). Research examined whether it was associated with changes in joint function and patient-reported pain in individuals with osteoarthritis.

  • Pain and Stiffness: Research evaluated changes in joint stiffness in the short term. One double-blind, randomized controlled trial (RCT) involving 450 participants evaluated whether the drug was associated with lower patient-reported pain scores compared to a placebo after four weeks.
  • Swelling and Function: A key study found that patients experienced a change in swelling over a 12-week period. This was one of the observations over time. Studies investigated whether this combination resulted in different outcomes regarding mobility compared to other treatments.
  • Study Duration: Research investigated the profile for long-term use, with some data covering up to one year of treatment. Studies observed a change in joint damage markers in a specific subgroup of patients.

Pediatric Population (Under 18)

Studies investigated the drug’s profile in juvenile idiopathic arthritis (JIA).

  • Safety Profile: Studies reported a certain safety profile in the individuals studied, and research has explored the need for caution in individuals with kidney issues.
  • Research Data: While preliminary data exists from smaller studies, the evidence for its use in patients under 18 remains limited, and evidence was restricted to specific clinical trials.

Pharmacokinetic Profile

Pharmacokinetic studies indicate the half-life of the drug in plasma was examined to be approximately 8 hours. Research has investigated the absorption of the drug as part of its pharmacokinetic profile.

  • Target Evaluation: Studies evaluated the drug’s interaction with Prostaglandin E2 (PGE2) receptors.

Frequently Asked Questions (FAQ)

Common questions about Cardiocare (FAQ)

Q: Is Cardiocare a type of blood thinner?

The official labeling describes Cardiocare as a lipid-regulating agent. While it is not formally classified as an anticoagulant (blood thinner), official information indicates that the medicine may prolong bleeding time. For this reason, official documents state that monitoring of patients taking it alongside other blood-clotting medications is required.

Q: What happens if I forget to take a dose of Cardiocare?

According to the official product information, if a dose is missed, regulatory information describes taking it as soon as it is remembered. However, regulatory documentation advises against taking a double dose to make up for a missed one. Consistent use, as defined by the prescribed regimen, is recommended.

Q: How does Cardiocare affect cholesterol levels?

Official warnings and precautions state that the product may increase low-density lipoprotein cholesterol (LDL-C) levels, which is sometimes referred to as 'bad' cholesterol. For this reason, official documents state that LDL-C levels require periodic monitoring by a healthcare provider while therapy is ongoing.

Q: Are there any contraindications related to previous stroke or heart attack history?

Regulatory reviews from the European Medicines Agency concluded that the medicine is no longer authorized for preventing further heart or blood vessel problems in patients who have already had a heart attack. However, official sources confirm it remains authorized for its primary use in managing high triglyceride levels (hypertriglyceridemia).

Q: Can Cardiocare be used by people who have diabetes?

Official patient counseling information emphasizes the need for patients to inform their doctor if they have diabetes. Clinical usage considerations note the importance of managing underlying medical conditions, such as diabetes, in the context of lipid abnormalities.

Q: What should be done if an allergic reaction to Cardiocare is suspected?

Official regulatory documents advise seeking immediate medical assistance if an allergic reaction is suspected—including symptoms like a rash, hives, or swelling of the face, throat, or tongue. This instruction is provided in official drug labels for managing serious safety concerns.

Q: Is there a high rate of discontinuation due to Cardiocare side effects?

Clinical trial data reported in the official prescribing information indicate that the rate of discontinuation of treatment specifically due to adverse events was 3.5% of patients. This provides a factual reference for the rate of treatment discontinuation observed in studies.

Q: Are headaches a frequent side effect of Cardiocare?

Headache is listed as a potential adverse event that was reported during clinical studies of the medicine. However, official regulatory documents do not classify headache among the list of most commonly reported side effects.

Q: Can Cardiocare affect my sleep?

Studies and official information indicate that insomnia (difficulty sleeping) has been reported as an adverse reaction during clinical trials or postmarketing experience. This suggests a possible, though not common, effect on sleep. If sleep disturbances are experienced, official guidance encourages reporting this information to a healthcare provider.

Q: Are mood changes or depression listed as potential side effects of Cardiocare?

Official information indicates that mood changes, specifically depression and emotional lability (rapid shifts in emotion), were reported as adverse events by some patients during clinical studies. These are noted as additional adverse events and are not generally listed among the most common effects.

Q: Can Cardiocare cause fatigue or tiredness?

Safety information from regulatory updates indicates that patients should consult a healthcare provider if tiredness is experienced. This is because unusual or persistent tiredness may be a symptom of Atrial Fibrillation, which is listed as a common side effect at higher doses.

How should Cardiocare be stored and disposed of?

The storage and disposal of Cardiocare (Omega-3 Fatty Acid softgels) must align strictly with regulatory requirements to preserve product quality and ensure safety.

Storage Requirement Official Constraint
Temperature Store at Controlled Room Temperature, typically 20°C to 25°C (68°F to 77°F). Do not freeze; avoid excessive heat.
Protection Keep in the original container, tightly closed, away from light and moisture.
Child-Safety Keep out of the sight and reach of children.

Maintaining these conditions is mandatory for product stability, as the active ingredients are sensitive to heat and oxidation. Regarding disposal, unused or expired Cardiocare must be discarded in accordance with local regulations. Regulatory documents explicitly state that the medicine should not be disposed of through household waste or wastewater to prevent environmental contamination, necessitating return to a proper pharmaceutical take-back location.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Cardiocare found in:

A-Z Index: